436 results on '"Bhatt, Deepak"'
Search Results
2. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
3. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
4. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI
5. Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trial
6. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?
7. Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials
8. Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction
9. Major Adverse Cardiovascular Events Across the Sotagliflozin Clinical Development Program
10. Socioeconomic disparities in healthcare utilization for atherosclerotic cardiovascular disease
11. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: A meta-analysis of randomized controlled trials
12. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)
13. Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
14. Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease
15. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction
16. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)
17. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
18. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap
19. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
20. Drug-eluting versus bare-metal stents for treating saphenous vein grafts
21. Renal function, atherothrombosis extent, and outcomes in high-risk patients
22. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
23. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
24. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
25. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease
26. Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents
27. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials
28. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: An American College of Cardiology National Cardiovascular Database Registry report
29. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
30. Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage
31. Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: Insights from the Veterans Affairs CART Program
32. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction
33. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis
34. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent
35. Prognostic significance of presenting blood pressure in non–ST-segment elevation acute coronary syndrome in relation to prior history of hypertension
36. Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study
37. Bare metal stent restenosis is not a benign clinical entity
38. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial
39. Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial
40. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers
41. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
42. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
43. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
44. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population
45. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting
46. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors
47. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
48. Impact of female sex on outcome after percutaneous coronary intervention
49. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
50. Preprocedural white blood cell count and death after percutaneous coronary intervention
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.